Atossa TherapeuticsMEX:ATOS -9.29%28 EV-to-FCF is 0.41 as of Jun. 25, 2026, which is 18% below its 10-year median of 0.50. GuruFocus rates MEX:ATOS with a GF Score™ of 28/100. The stock has 2 warning signs investors should review. Among 330 Biotechnology companies, Atossa Therapeutics ranks better than 87.27% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Atossa Therapeutics's Enterprise Value is MXN-250.44 Mil.
Atossa Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-609.63 Mil. Therefore, Atossa Therapeutics's EV-to-FCF for today is 0.41.
The historical rank and industry rank for Atossa Therapeutics's EV-to-FCF or its related term are showing as below:
MEX:ATOS'
s EV-to-FCF Range Over the Past 10 Years
Min: -0.78 Med: 0.5 Max: 0.54
Current: 0.43
During the past 13 years, the highest EV-to-FCF of Atossa Therapeutics was 0.54. The lowest was -0.78. And the median was 0.50.
MEX:ATOS's EV-to-FCF is ranked better than 87.27% of 330
companies
in the Biotechnology industry
Industry Median: 14.97
vs MEX:ATOS: 0.43
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Atossa Therapeutics's PE Ratio (TTM) for today is calculated as:
Atossa Therapeutics's share price for today is MXN31.75.
Atossa Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-83.314.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Atossa Therapeutics EV-to-FCF Related Terms
Atossa Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Atossa Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ATOS vs LTRN, ESLA, NTRB: EV-to-FCF Comparison
For the Biotechnology subindustry, Atossa Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atossa Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Atossa Therapeutics's EV-to-FCF falls into.
Atossa Therapeutics's current Enterprise Value is MXN-250.44 Mil.
Atossa Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN-609.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atossa Therapeutics (MEX:ATOS) has a EV-to-FCF of 0.41 as of Jun. 25, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Atossa Therapeutics and its competitors. This is 18% below median its historical median of 0.50. According to the industry distribution chart, Atossa Therapeutics ranks #42 out of 330 companies in the Biotechnology industry, placing it in the top 12.7%.
Is Atossa Therapeutics' EV-to-FCF too high?
Atossa Therapeutics' current EV-to-FCF of 0.41 is 18% below median its 10-year median of 0.50. The Biotechnology industry median EV-to-FCF is 14.97. Atossa Therapeutics' value of 0.41 is 97.3% below this industry median. Based on the distribution chart, Atossa Therapeutics ranks #42 out of 330 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' EV-to-FCF compare to LTRN and ESLA?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #42 out of 330 companies for EV-to-FCF. This places Atossa Therapeutics in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 14.97. Atossa Therapeutics' value of 0.41 is 97.3% below this benchmark. While the company's 10-year median is 0.50 vs. the industry median of 14.97, Atossa Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.97, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Atossa Therapeutics's current EV-to-FCF of 0.41 is 97.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Atossa Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atossa Therapeutics's current EV-to-FCF is 0.41, which is 18% below median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (MEX:ATOS) has a current EV-to-FCF of 0.41. The current EV-to-FCF is 0.41, which is 18% below median its 10-year median of 0.50 and 97.3% below the Biotechnology industry median of 14.97. Atossa Therapeutics' overall GF Score™ is 28/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Atossa Therapeutics (MEX:ATOS), the current EV-to-FCF is 0.41 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
28GF Score
Get the complete analysis for MEX:ATOS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ATOS has been successfully added to your 
